Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile
2. Tvb-2640
1. Tvb-2640
2. 1399177-37-7
3. Denifanstat [inn]
4. Denifanstat [usan]
5. Fasn-in-2
6. 4gf95b2lza
7. Tvb 2640 [who-dd]
8. 4-(1-(4-cyclobutyl-2-methyl-5-(3-methyl-1h-1,2,4-triazol-5-yl)benzoyl)piperidin-4-yl)benzonitrile
9. 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4h-1,2,4-triazol-3- Yl)benzoyl)piperidin-4-yl)benzonitrile
10. 4-(1-(4-cyclobutyl-2-methyl-5-(5-methyl-4h-1,2,4-triazol-3-yl)benzoyl)piperidin-4-yl)benzonitrile
11. Us8871790, 480
12. 4-[1-[4-cyclobutyl-2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl]benzonitrile
13. 4-{1-[4-cyclobutyl-2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)benzoyl]piperidin-4-yl}benzonitrile
14. Benzonitrile, 4-(1-(4-cyclobutyl-2-methyl-5-(3-methyl-1h-1,2,4-triazol-5-yl)benzoyl)-4-piperidinyl)-
15. Benzonitrile, 4-[1-[4-cyclobutyl-2-methyl-5-(3-methyl-1h-1,2,4-triazol-5-yl)benzoyl]-4-piperidinyl]-
16. Unii-4gf95b2lza
17. Asc-40
18. Chembl3661754
19. Schembl12488853
20. Bdbm137084
21. Bcp30428
22. Ex-a3643
23. S9714
24. Who 11784
25. Zinc150188638
26. Ac-35714
27. Hy-112829
28. Cs-0066310
29. Tvb2640; Tvb 2640;fasn-in-2
30. A937502
31. Us8871790, 152
Molecular Weight | 439.6 g/mol |
---|---|
Molecular Formula | C27H29N5O |
XLogP3 | 5.3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 439.23721057 g/mol |
Monoisotopic Mass | 439.23721057 g/mol |
Topological Polar Surface Area | 85.7 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 728 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.
Lead Product(s): Denifanstat
Therapeutic Area: Dermatology Brand Name: ASC40
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ascletis Completes ASC40 Phase III Trial Enrollment for Acne
Details : ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.
Brand Name : ASC40
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 12, 2024
Details:
TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Details : TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.
Brand Name : TVB-2640
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2024
Details:
TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sagimet Completes Phase 1 Hepatic Impairment Study of FASN Inhibitor Denifanstat
Details : TVB-264 (denifanstat) is a selective FASN inhibitor, which is under clinical development for the treatment of metabolic dysfunction-associated steatohepatitis/Non-alcoholic Steatohepatitis.
Brand Name : TVB-2640
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 27, 2024
Details:
TVB-2640 (denifanstat) is an orally bioavailable fatty acid synthase (FASN) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of Nonalcoholic Fatty Liver Disease.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sagimet Announces Positive Results from Phase 2b of Denifanstat in F2/F3 NASH
Details : TVB-2640 (denifanstat) is an orally bioavailable fatty acid synthase (FASN) inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of Nonalcoholic Fatty Liver Disease.
Brand Name : TVB-2640
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 23, 2024
Details:
TVB-2640 (denifanstat) is an oral, selective FASN inhibitor which is under phase 2 clinical development for the treatment of non-alcoholic steatohepatitis patients with stage 2 or stage 3 fibrosis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gannex's Partner Sagimet Announces Positive Results From Phase 2b Trial Of Denifanstat
Details : TVB-2640 (denifanstat) is an oral, selective FASN inhibitor which is under phase 2 clinical development for the treatment of non-alcoholic steatohepatitis patients with stage 2 or stage 3 fibrosis.
Brand Name : TVB-2640
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 22, 2024
Details:
ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.
Lead Product(s): Denifanstat
Therapeutic Area: Dermatology Brand Name: ASC40
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Lead Product(s) : Denifanstat
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ASC40 (Denifanstat) is a FASN inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of acne vulgaris via oral tablet.
Brand Name : ASC40
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in combined with bevacizumab for the treatment of recurrent glioblastoma.
Lead Product(s): Denifanstat,Bevacizumab
Therapeutic Area: Oncology Brand Name: ASC40
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Ascletis Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Lead Product(s) : Denifanstat,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Ascletis Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated in combined with bevacizumab for the treatment of recurrent glioblastoma.
Brand Name : ASC40
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated for the treatment of mild-moderate acne vulgaris.
Lead Product(s): Denifanstat
Therapeutic Area: Dermatology Brand Name: ASC40
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Lead Product(s) : Denifanstat
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN). It is being investigated for the treatment of mild-moderate acne vulgaris.
Brand Name : ASC40
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 02, 2023
Details:
ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN), a key enzyme which regulates DNL. Human sebum production requires de novo lipogenesis, which is increased in acne and can be suppressed by the FASN inhibitor ASC40.
Lead Product(s): Denifanstat
Therapeutic Area: Dermatology Brand Name: ASC40
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Lead Product(s) : Denifanstat
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ASC40 (denifanstat) is an oral, selective small molecule inhibitor of fatty acid synthase (FASN), a key enzyme which regulates DNL. Human sebum production requires de novo lipogenesis, which is increased in acne and can be suppressed by the FASN inhibito...
Brand Name : ASC40
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2022
Details:
Denifanstat (TVB-2640) is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis.
Lead Product(s): Denifanstat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: TVB-2640
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Lead Product(s) : Denifanstat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Denifanstat (TVB-2640) is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis.
Brand Name : TVB-2640
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2022
ABOUT THIS PAGE
A Denifanstat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Denifanstat, including repackagers and relabelers. The FDA regulates Denifanstat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Denifanstat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Denifanstat supplier is an individual or a company that provides Denifanstat active pharmaceutical ingredient (API) or Denifanstat finished formulations upon request. The Denifanstat suppliers may include Denifanstat API manufacturers, exporters, distributors and traders.
Denifanstat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Denifanstat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Denifanstat GMP manufacturer or Denifanstat GMP API supplier for your needs.
A Denifanstat CoA (Certificate of Analysis) is a formal document that attests to Denifanstat's compliance with Denifanstat specifications and serves as a tool for batch-level quality control.
Denifanstat CoA mostly includes findings from lab analyses of a specific batch. For each Denifanstat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Denifanstat may be tested according to a variety of international standards, such as European Pharmacopoeia (Denifanstat EP), Denifanstat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Denifanstat USP).
LOOKING FOR A SUPPLIER?